Clinical Trials Logo

Graves Ophthalmopathy clinical trials

View clinical trials related to Graves Ophthalmopathy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT06087731 Withdrawn - Clinical trials for Thyroid Associated Ophthalmopathy

Efficacy and Safety of Tocilizumab for TAO

Start date: September 23, 2023
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

NCT ID: NCT02422368 Withdrawn - Thyroid Eye Disease Clinical Trials

The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease

Start date: September 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

ASTED (Antioxidant Supplements for TED) trial is an investigator-initiated, randomized, triple masked, clinical trial of a selected combination of vitamins and minerals versus placebo in patients with moderate to severe thyroid eye disease. The trial has a parallel-arm design.

NCT ID: NCT02393183 Withdrawn - Thyroid Eye Disease Clinical Trials

The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)

Start date: July 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED: 1. β- Carotene (30 mg) 2. Vit C (100 mg) 3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU 4. Calcium phosphate dihydrate (40 mg) 5. Zinc oxide (4 mg, elemental) 6. Copper gluconate (3.5 mg) 7. Sodium selenite 23 mg= Selenium 100 µg 8. Nicotinamide (a form of vit.B3) (10 mg) in patients with mild Thyroid eye disease according to EUGOGO classification. To be given twice a day.

NCT ID: NCT02112643 Withdrawn - Clinical trials for Thyroid Associated Ophthalmopathies

Selenium in Mild Thyroid Eye Disease in North America

S-ITEDS
Start date: October 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether sodium selenite is helpful in the treatment of mild thyroid eye disease in North America.

NCT ID: NCT01927406 Withdrawn - Glaucoma Clinical Trials

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Start date: June 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims to determine if PA would change the course of the orbitopathy in TED patients by altering the progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease and elevated intraocular pressure will be randomised to the PA treatment and the other eye will serve as a control eye and will be treated with Timolol.

NCT ID: NCT01379196 Withdrawn - Clinical trials for Graves Ophthalmopathy

Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy

Start date: May 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine the effects of Azithromycin (a macrolide class antibiotic), given three times weekly, for patients with active moderate-severe, non sight-threatening, Graves Orbitopathy. Indices for follow-up will include: - Clinical activity score - Anti-TSH receptor antibody levels - Thickening of extraocular muscles per ultrasound - Quality of life score for Graves Orbitopathy patients

NCT ID: NCT01272414 Withdrawn - Clinical trials for Graves Ophthalmopathy

Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction

Start date: January 2011
Phase: Phase 4
Study type: Interventional

Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent stage lid position. This investigation aims to examine the properties of this relationship.